Influenza epidemiology and risk factors for severe acute respiratory infection in Morocco during the 2016/2017 and 2017/2018 seasons

Hind Ezzine, Imad Cherkaoui, Ahmed Rguig, Hicham Oumzil, Mouad Mrabet, Abderrahman Bimouhen, Fatima El Falaki, Zakia Reagrugi, Zineb Tarhda, Mohammed Youbi, Mariam Naciri

Corresponding author: Hind Ezzine, Directorate of Epidemiology and Disease Control, Ministry of Health, Morocco. hindezzine3@gmail.com

Received: 09 Dec 2019 - Accepted: 02 Feb 2020 - Published: 07 Jul 2020

Keywords: Influenza positivity rate, influenza risk factor, influenza-like illness, severe acute respiratory infections, co-morbidity

Copyright: Hind Ezzine et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Hind Ezzine et al. Influenza epidemiology and risk factors for severe acute respiratory infection in Morocco during the 2016/2017 and 2017/2018 seasons. Pan African Medical Journal. 2020;36(159). 10.11604/pamj.2020.36.159.21239

Available online at: https://www.panafrican-med-journal.com/content/article/36/159/full
Abstract

Introduction: in order to implement an influenza vaccination program for high-risk-groups in Morocco, as recommended by the World Health Organization, an epidemiological study indicating the influenza virus effect in the development of complicated influenza for subjects with comorbidity was required. The present study aims to evaluate the risk factors for severe acute respiratory infections caused by influenza in risk groups. Methods: this research is based on the epidemiological and virological surveillance data of severe acute respiratory infections and influenza-like illness during the 2016/2017 and 2017/2018 seasons. It was realized using a retrospective series study with a descriptive and analytical purpose. Results: the over-recruitment of pediatric cases with a severe acute respiratory infection has been significantly rectified because cases of severe acute respiratory infections under 15 years old in the 2017/2018 season represent only 57.9%, whereas they represented 75.9% of the total cases of severe acute respiratory infections during the 2016/2017 season. The influenza positivity rate has increased globally and specifically by age group, clinical service and co-morbidity. The risk factors considered were significantly associated with hospitalization for influenza-associated severe acute respiratory infections. The multivariate logistic regression analysis considers male sex (OR=2.1), age ≥65 years (OR=5.4), presence of influenza cases in the surroundings (OR=0.1), diabetes (OR=7.5) and chronic respiratory disease (OR=10.9) as risk factors influenza-associated severe acute respiratory infections. Conclusion: the risk assessment of influenza-associated severe acute respiratory infections in high-risk groups revealed national epidemiological findings, particularly for diabetics and the elderly. An influenza vaccination program for these high-risk groups becomes much recommended in Morocco.

Introduction

The seasonal influenza is an acute viral infection of the respiratory tract with high contagious effects. Both type A and B influenza viruses are responsible for seasonal epidemics of clinical influenza [1] which progress as Influenza-like illness (ILI), generally benign. Hence, in terms of morbidity, mortality and social costs, they impose a huge burden [2]. Hospitalization and deaths mainly occur in high-risk-groups due to severe acute respiratory infections (SARI). The seasonal epidemics affect about 9% of the world population each year [3] and cause about 3 to 5 million cases of serious diseases. Six hundred and fifty thousand deaths annually are associated with respiratory diseases caused by seasonal influenza [4]. Since the 1960s, the World Health Organization (WHO) has produced numerous resolutions and recommendations to take into account the morbidity and mortality burden of seasonal influenza epidemics. It also invited the member states to strengthen active influenza surveillance and vaccination programs, particularly for specific risk groups [5-8]. However, many countries around the world continue to have low immunization rates due to skepticism about the vaccine’s efficacy [9-11]. The Moroccan sentinel system for epidemiological and virological surveillance of SARI and ILI was implemented in 2007 as part of the pandemic influenza response with the support of the Centers for Disease Control and Prevention of Atlanta, United States of America (US-CDC) [12].

Then, in 2014, it was redeployed in eight hospital and ambulatory sentinel sites. In 2013, the Moroccan Ministry of Health, responding to the recommendations of the WHO-SAGE committee concerning the influenza vaccination of risk groups [8], established a cooperation agreement with the US-CDC in order to extend the influenza vaccination to other risk groups in addition to health personnel. This project aims to conduct epidemiological and operational studies in order to demonstrate, to the national immunization technical advisory group (national technical and
scientific advisory vaccination committee), the relevance of the influenza vaccination strategy \[13\]. Thus, the Moroccan Ministry of Health established in 2015 a prevention and control program for SARI and ILI, which expressed its information and monitoring needs. The evaluation of the surveillance system data collected during the 2015/2016 season revealed an over-recruitment bias in cases of pediatric SARI at sentinel hospital sites. 59.3% of the total cases of SARI recruited during this season are less than 4 years old \[14\]. Hence, many activities have been planned and carried out during the 2017/2018 season to rectify the recruitment bias observed at sentinel hospital sites in the previous season. In the present study, the results of epidemiological and virological surveillance of SARI and ILI in the 2016/2017 season were compared with those of the 2017/2018 season and the risk factors for influenza-associated SARI hospitalization were evaluated whatever the type of influenza viruses identified in confirmed influenza cases during the two seasons.

**Methods**

**Type of study:** in this research, we have used a retrospective case series study with descriptive and analytical purpose.

**Study sample:** the case series includes cases of SARI and ILI collected as part of the epidemiological and virological surveillance that was implemented by the Moroccan Ministry of Health during the 2016/2017 and 2017/2018 seasons. The definition of ILI and SARI cases is the same as that used in the surveillance system which was updated in 2014 by the Ministry of Health \[15\] according to WHO's definitions \[16\].

**Severe acute respiratory infection:** this is a person suffering from an acute respiratory infection that includes: fever or a history of fever \(\geq 38^\circ C\); cough; beginning of the disease in the last ten days; and which requires hospitalization. According to clinicians in sentinel hospitals, some patients may not develop a fever even if they have a viral infection due to metabolic and immune disorders. Therefore, some cases of SARI with co-morbidity were considered for recruitment purposes as meeting the case definition despite the absence of fever.

**Cases of ILI:** it is an acute respiratory infection that includes: measured fever \(\geq 38^\circ C\); cough; and the beginning of the disease in the last ten days.

**Study sites:** eight public ambulatory and hospital sentinel sites: Rabat, Tangiers, Fez, Marrakech, Meknes, Beni Mellal, Oujda and Agadir and the private ambulatory network of medical practitioners were included in this study.

**Data collection:** the cases of SARI were collected by realizing a nasal and pharyngeal sampling immediately after admission to pediatric, pulmonary, medical and emergency wards or intensive care units as well as to the maternity wards of the sentinel hospital sites. The cases of ILI were collected in sentinel health centers. A questionnaire was successfully completed with patient identification data, clinical data, epidemiological data including vaccination, notion of travel and similar cases in the surroundings; results of virological analysis and information on the patient's evolution, particularly his death during hospitalization.

**Statistical analysis:** data collected from the questionnaires of SARI and ILI cases were extracted as an Excel file from the web application. The statistical analysis was carried out using the Epi-Info 7 and SPSS software in 2 phases: 1°) a descriptive phase of epidemiological and virological surveillance data of SARI and ILI cases; 2°) an
analytical phase (bivariate and multivariate analysis by logistic regression) in order to identify the risk factors of influenza-associated SARI whatever the type of influenza viruses identified. Only the cases of influenza confirmed by the laboratory during the two influenza seasons 2016/2017 and 2017/2018 were included in this analysis. The variable of interest in this study was the hospitalization due to the development of an influenza-associated SARI. The explicative variables studied were the potential risk factors related to personal socio-demographic characteristics, epidemiological context and the presence of co-morbidity. The statistical significance level was fixed at 5%.

Results

A total of 2622 patients were recruited during the two seasons. In 2016/2017 season, 1359 samples were collected and 1263 samples in 2017/2018 season (Figure 1). The proportion of SARI increased from one season to the other from 51.8% (n=704) to 64.8% (n=819). As shown in Figure 2, the proportion of SARI under 15 years old in the 2017/2018 season was 57.9%, while it represented 75.9% of the total number of SARI recruited during the 2016/2017 season. In Table 1, it is noted that the increase in recruitment of non-pediatric SARI cases has mainly concerned pulmonology, medicine and emergency wards as well as intensive care units. Similarly, the recruitment of SARI with co-morbidity has also increased from one season to the other, as shown in Table 2. According to the case definition used for recruitment, fever, cough and the beginning of signs within ten days were found in respectively 89.1%, 91.5% and 90.7% of SARI cases and in respectively 98.0%, 95.6% and 98.0% of ILI cases when both seasons cases were considered. The overall positivity rate is statistically higher during the 2017/2018 season compared to the 2016/2017 season (respectively 20.1% versus 10.4%, p<10^-6). This increase is also individually observed for ILI and SARI as illustrated in Figure 1. The specific positivity rate per co-morbidity has also increased significantly, reaching values higher than 6% of the global positivity during the 2017/2018 season, particularly for diabetes, asthma and chronic respiratory disease.

The participation of pregnant women remained very low during both seasons, as shown in Table 2, with recruitment of 9 and 5 pregnancy cases respectively. Figure 3 and Figure 4 illustrate that during the two seasons, the age range of 65 years and over in SARI cases and 5-15 years in ILI cases had the highest positivity rates with 20.7% and 36.0% respectively. The analysis of hospitalization risk factors for influenza-associated SARI was conducted on a sample of 381 influenza positive cases whatever clinical syndrome during the two seasons (except for pregnancy where only 198 female cases were considered). The risk factors considered in the bivariate analysis as shown in Table 3 and found significantly associated with hospitalization caused by influenza-associated SARI, included male sex (OR=2.2), age >65 years (OR=10.6), presence of influenza cases in the surroundings (OR=0.1), diabetes (OR=8.8), asthma (OR=10.1), chronic respiratory disease (OR=17.7), chronic heart disease (OR=4.2), chronic renal failure (OR=12.2) and chronic hematological disease (OR indeterminate). The multivariate analysis by logistic regression after adjustment for all previous risk factors, retained in the final model the male sex (OR=2.1 with CI 95%=[1.3-3.5] and p=0.005), age ≥65 years (OR=5.4 with CI 95%=[1.9-15.6] and p=0.002), the presence of influenza cases in the surroundings (OR=0.1 with CI 95%=[0.05-0.3 and p<10^-3], diabetes (OR=7.5 with CI 95%=[1.7-32.8] and p=0.007) and chronic respiratory disease (OR=10.9 with CI 95%=[2.0-58.4] and p=0.005). These results are summarized in Table 4.

Discussion

Since 2006, in response to the pandemic risk, several international and governmental institutions, such as WHO and US-CDC, have invested in partnership with African countries to develop their epidemiological surveillance and laboratory diagnostic capacities in the field of influenza. In 2009, the African network for influenza surveillance and epidemiology (ANISE),
Involving more than 30 African countries, was deployed to generate and disseminate data on influenza morbidity and mortality in Africa [17]. Influenza surveillance data from 2006 to 2010 obtained in 15 African countries, including two North African countries, Morocco and Egypt [18], showed that 21.7% of ILI cases (5165/69860) and 10.1% of SARI cases (4427/43620) were tested positive for influenza [19]. Similar to our case series, influenza is therefore detected consistently with a higher proportion for ILI cases compared to SARI cases, which probably reflects the higher sensibility of the ILI case definition compared to the SARI case definition. However, these results are slightly higher than those reported by other resource-limited countries outside Africa such as Bangladesh where the positivity rate is only 10% for ILI cases and 6% for SARI cases [20] as well as Cambodia and Indonesia with similar results [21,22]. In the African multicenter study, the burden of respiratory diseases and influenza was highest among children less than 5 years of age, which is consistent with other studies conducted in the region [23,24].

The children are probably over-represented, which explains the low proportions of influenza infection in the older age range. The efforts made at the start and during the 2017/2018 influenza season to reactivate the sentinel system of epidemiological and virological surveillance in Morocco have successfully limited the recruitment bias of cases of pediatric, while the recruitment of ILI cases was adequately represented in each age range from one season to the other. The influenza positivity rate results obtained in 2017/2018 season, with 11.9% for SARI cases, were very close to the average of 15 African countries. However, the influenza positivity rate was 34.8% for ILI cases, which is much higher, indicating a better recruitment of ILI cases in Morocco. The risk assessment of influenza infection according to age group in the two seasons 2016/2017 and 2017/2018 has revealed that influenza infection in Morocco mainly affects SARI cases over the age of 65 with an influenza positivity rate of 20.7%. The influenza positivity rate in SARI cases under 2 years of age remains relatively low in Morocco during the study period with 4.4%, which is consistent with the results of international [25-28] and national [29] studies showing the preponderance of other viruses such as rhinovirus and RSV in children with bronchoalveolitis.

In contrast, the 5-15 age range has the highest influenza positivity rate in ILI cases, with 36.0%, probably due to school exposure. Despite the progress in the management of serious infectious diseases, community pneumonia, which is the major clinical presentation of SARI cases, remains the primary cause of hospitalization and death in developed countries [30, 31]. The influenza virus causes about 6.5% of all cases of pneumonia [32] and up to 64% of their viral cause [33]. Available studies on the impact of influenza virus infection on morbidity and mortality in low-income countries are particularly limited, although this impact may be amplified by specific factors such as overpopulation and inadequate access to health services. However, if the vast majority of patients have benign influenza during seasonal peaks, other patients with specific risk factors will develop a severe acute respiratory infection [34]. Hence, an increase in the number of cases of acute asthma [35], acute exacerbation of chronic obstructive pulmonary disease (COPD) [36], decompensating of metabolic diseases (diabetes) [37], cardiac diseases [38] or other [39-41] and an increase in hospitalizations for extreme ages (children and elderly people) [42] as well as pregnant women [43] are usually observed. This leads rapidly to an overload of admission capacities of emergency wards and intensive care units (ICUs) [44], where clinical management of this type of infection will depend mainly on the patient’s condition rather than the virulence of the virus.

In bivariate analysis of our study for both seasons, the majority of co-morbidities recommended by WHO for influenza vaccination are strongly associated with the hospitalization for influenza-associated SARI whatever the type of virus identified (age ≥65 years, diabetes, asthma, chronic respiratory disease, chronic heart disease, chronic kidney failure and hematologic disease). The other
factors such as pregnancy and neurological disease recruited in very small numbers did not have sufficient statistical power to assess their risk. Thus, the multivariate logistic regression model retains only three risk factors after adjustment, namely age ≥65 years, diabetes and chronic respiratory disease. The risk associated with chronic renal failure remains at the limit of statistical significance where p=7% whereas the risk of chronic heart disease is certainly the subject of a confounding effect due to the statistical association with the presence of diabetes. It should be noted that the last two diseases are often associated in current clinical practice. These risk factors are usually found associated with hospitalization for influenza-associated SARI cases in several studies carried out in both low-income and developed countries in particular for extremes of age, diabetes, chronic respiratory diseases as asthma and HIV when the prevalence is high [45-49]. In addition, male sex is statistically strongly associated with the hospitalization for influenza-associated SARI due to the over-recruitment of women with ILI at sentinel health centers. Moreover, the presence of influenza cases in the surroundings appears to have a protective effect on the risk of hospitalization for SARI due to the fact that ambulatory subjects recruited from sentinel health centers are more exposed to the dissemination of the virus than subjects with SARI recruited in a closed hospital environment.

Conclusion

In this study, the analysis of epidemiological and virological sentinel surveillance data collected during the 2016/2017 and 2017/2018 seasons allowed us to assess the risk of hospitalization due to the occurrence of influenza-associated SARI. Consequently, this evaluation provides national epidemiological evidence, particularly for diabetics and elderly persons. As recommended by the WHO, an influenza vaccination program for these high-risk-groups is therefore highly appropriate in Morocco. Finally, in order to assess other risk factors, particularly pregnancy, further studies should be conducted with larger samples.

What is known about this topic

- Following a comprehensive review of the influenza disease burden, vaccine performance and safety in populations of all ages and at-risk groups, incorporating available data from low and middle-income country settings, the WHO strategic advisory group of experts (SAGE) on immunization met on 10-12 April 2012 in Geneva, Switzerland and recommended pregnant women as the most important risk group for inactivated seasonal influenza vaccination. Other risk groups to be considered, in no specific priority order were: health-care workers; children aged 6-59 months; the elderly and those with high risk conditions (Reference: WER No. 21, 2012, 87, 201-216).

What this study adds

- At the request of the Morocco national immunization technical advisory group (NITAG) and before the implementing of the Morocco influenza vaccination strategy targeting high risk groups as recommended by WHO, the influenza surveillance team carried out epidemiological studies based on data provided by the influenza surveillance system to produce the evidence in Morocco of the influenza vaccination benefit as done by WHO at international level.

Competing interests

The authors declare no competing interests.

Authors' contributions

EH, CI and MM designed the study, performed data analysis and interpretation of results; CI helped with data collection; OH, BA, FF, RZ assisted with access to laboratory data and interpretation of laboratory results; YM assisted with study implementation; EH, CI and TZ wrote the paper; TZ
assisted with editing of the manuscript; NM provided pedagogic support, corrected the manuscript and has given approval of the final version to be published. All the authors have read and agreed to the final manuscript.

Acknowledgments

We acknowledge support from the National Influenza Center at the National Institute of Hygiene and the Directorate of Epidemiology and Disease Control, Ministry of Health, of Morocco. We also thank Professor Maaroufi Aberrahmane for his contribution.

Tables and figures

Table 1: number of SARI cases recruited and their influenza positivity rates per clinical ward (2016/2017 and 2017/2018 season)

Table 2: number of SARI cases with co-morbidities sampled and their influenza positivity rate (2016/2017 and 2017/2018 season)

Table 3: bi-variate analysis for evaluating the risk factors of influenza-associated SARI with a sample of 381 influenza-positive cases (2016/2017 and 2017/2018 season)

Table 4: multivariate logistic regression model for evaluating the risk factors of influenza-associated SARI with a sample of 381 influenza-positive cases (2016/2017 and 2017/2018 season)

Figure 1: influenza positivity rate by clinical syndrome (2016/2017 and 2017/2018 season)

Figure 2: SARI cases per age range (2016/2017 and 2017/2018 season)

Figure 3: positive rate per age range of SARI cases, all-season combined (2016/2017 and 2017/2018 season)

Figure 4: positive rate per age range of ILI cases, all seasons combined (2016/2017 and 2017/2018 season)

References

1. World Health Organization. Influenza (Seasonal). 2018. Accessed on December 09 2019.
2. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and health care resource utilization in a working population. Occup Med. 1998;48(2): 85-90. PubMed | Google Scholar
3. Ghendon Y. Influenza- its impact and control. Rapp Trimest Statist Sanit Mond. 1992;45(2-3): 306-311. PubMed | Google Scholar
4. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet. 2018;391(10127): 1285-1300. PubMed | Google Scholar
5. World Health Organization. Twenty-second World Health Assembly: Boston, Massachusetts, 8-25 July 1969: part I: resolutions and decisions: annexes. WHO. 1969. Google Scholar
6. World Health Organization. Forty-eighth World Health Assembly Geneva, 1-12 MAY 1995 resolutions and decisions annexes. WHO. 1995.
7. World Health Organization. Prevention and control of influenza pandemics and annual epidemics WHA56.19. WHO. 2003.
8. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012--conclusions and Recommendations. Weekly Epidemiological Record (WER). 2012: 87(21): 201-216. PubMed | Google Scholar
9. Kurinczuk JJ, Nicholson KG. Uptake of influenza vaccination by patients with serious cardiac disease. BMJ. 1989;299(6695): 367. PubMed | Google Scholar
10. Nicholson KG, Wiselka MJ, May A. Influenza vaccination of the elderly: perceptions and policies of general practitioners and outcome of the 1985-86 immunisation program in Trent, UK. Vaccine. 1987;5(4): 302-6. PubMed | Google Scholar
11. Lennox IM, Macphee GJA, Mc Alpine CH, Cameron SO, Leask BGS, Somerville RG. Use of influenza vaccine in long-stay geriatric units. Age Ageing. 1990;19(3): 169-72. PubMed | Google Scholar
12. Barakat A, Ihazmad H, Benkaroum S, Cherkaoui I, Benmamoun A, Youbi M et al. Influenza surveillance among outpatients and inpatients in Morocco, 1996-2009. PLoS ONE. 2011;6(9): e24579. PubMed | Google Scholar
13. Ministry of Health. Decision of the Ministry of Health No. 12536 of 6 July 2015 establishing a National Technical and Scientific Advisory Committee on Immunization. 2015. Accessed on December 09 2019.
14. Sakhri N. Rapport: analyse des données et évaluation du système de surveillance épidémiologique et virologique de la grippe au Maroc. Cycle de Mastère en Administration Sanitaire et Santé Publique Promotion: 2015-2017 - Filière: Epidémiologie de Santé Publique. Ecole National de Santé Publique (Maroc). (Internal document of the National Public Health School of Morocco).
15. Manuel de procédures du système de surveillance de la grippe au Maroc (2014). Ministère de la santé, Direction de l’Épidémiologie et de la Lutte contre les Maladies. (Internal document of the Ministry of Health of Morocco).
16. World Health Organization. WHO surveillance case definitions for ILI and SARI. 2014. Accessed on December 09 2019.
17. Centers for Disease Control and Prevention. The African Network for Influenza Surveillance and Epidemiology (ANISE). Accessed on December 09 2019.
18. Elhakim M, Rasooly MH, Fahim M, Ali SS, Haddad N, Cherkaoui I et al. Epidemiology of severe cases of influenza and other acute respiratory infections in the Eastern Mediterranean Region, July 2016 to June 20. J Infect Public Health. 2020 Mar;13(3): 423-429. PubMed | Google Scholar
19. Radin JM, Katz MA, Tempia S, Nzussouo NT, Davis R, Duque J et al. Influenza surveillance in 15 countries in Africa, 2006-2010. JID. 2012;206(Suppl 1): S14-S21. PubMed | Google Scholar
20. Zaman RU, Alamgir AS, Rahman M, Azziz-Baumgartner E, Gurley ES, Sharker MAY et al. Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh,2007-2008. PLoS One. 2009;4(12): e8452. PubMed | Google Scholar
21. Mardy S, Ly S, Heng S, Vong S, Huch C, Nora C et al. Influenza activity in Cambodia during 2006-2008. BMC Infect Dis. 2009;9: 168. PubMed | Google Scholar
22. Beckett CG, Kosasi h H, Ma´ roef C, Listiyaningsih E, Elyazar IR, Wuryadi S et al. Influenza surveillance in Indonesia: 1999-2003. Clin Infect Dis. 2004;39(4): 443-9. PubMed | Google Scholar
23. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807): 1917-30. PubMed | Google Scholar
24. Razanajatovo NH, Richard V, Hoffmann J, Reynes J, Razafitrimo GM, Randremanana RV et al. Viral etiology of influenza-like illnesses in Antananarivo, Madagascar, July 2008 to June 2009. PLoS One. 2011;6(3): e17579. PubMed | Google Scholar
25. Demers AM, Morency P, Mberyo-Yaah F, Jaffar S, Blais C, Somse P et al. Risk factors for mortality among children hospitalized because of acute respiratory infections in Bangui, Central African Republic. Pediatr Infect Dis J. 2000;19(5): 424-32. PubMed | Google Scholar
26. Djelantik IG, Gessner BD, Sutanto A, Steinhoff M, Linehan M, Moulton LH et al. Case fatality proportions and predictive factors for mortality among children hospitalized with severe pneumonia in a rural developing country setting. J Trop Pediatr. 2003;49(6): 327-32. PubMed | Google Scholar
27. Suwanjutha S, Ruangkanchanasetr S, Chantarojanasiri T, Hotrakitya S. Risk factors associated with morbidity and mortality of pneumonia in Thai children under 5 years, Southeast Asian. J Trop Med Public Health. 1994;25(1): 60-6. PubMed | Google Scholar
28. Tiewsoh K, Lodha R, Pandey RM, Broor S, Kalaivani M, Kabra SK. Factors determining the outcome of children hospitalized with severe pneumonia. BMC Pediatr. 2009;9: 15. PubMed | Google Scholar
29. Jroundi I, Mahraoui C, Benmessaoud R, Moraleda C, Tligui H, Seffar M et al. Risk factors for a poor outcome among children admitted with clinically severe pneumonia to a university hospital in Rabat, Morocco. International Journal of Infectious Diseases. 2014;28: 164-170. PubMed | Google Scholar
30. Marrie TH, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11(4): 86-99. PubMed | Google Scholar
31. Torres A, Serra-Batllés J, Ferrer A, Jiménez P, Celis R, Cobo E et al. Severe community acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144(2): 312-318. PubMed | Google Scholar
32. Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respiratory Medicine. 2005;99(9): 1079-86. PubMed | Google Scholar
33. De Roux A, Marcos MA, Garcia E, Mensa J, Ewig S, Lode H et al. Viral community-acquired pneumonia in non-immuno-compromised adults. Chest. 2004;125(4): 1343-51. PubMed | Google Scholar
34. Thomas RE. Do we have enough evidence how seasonal influenza is transmitted and can be prevented in hospitals to implement a comprehensive policy. Vaccine. 2016;34(27): 3014-21. PubMed | Google Scholar
35. Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Frontiers in Microbiology. 2013;4: 293. PubMed | Google Scholar
36. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct.Pulmon Dis. 2014;9: 1101-10. PubMed | Google Scholar
37. Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicenter cohort studies. Thorax. 2010 October;65(10): 870-877. PubMed | Google Scholar
38. Boari B, Mari E, Gallerani M, Fabbian F, Pala M, Tiseo R et al. Temporal variation of heart failure hospitalization: does it exist. Rev Cardio Vasc Med. 2011;12(4): 211-8. PubMed | Google Scholar
39. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008: 121(4): 258-64. PubMed | Google Scholar
40. Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF et al. Influenza Circulation and the Burden of Invasive Pneumococcal Pneumonia During a Non-Pandemic Period in the United States. Clin Infect Dis. 2010;50(2): 175-83. PubMed | Google Scholar
41. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6(5): 303-12. PubMed | Google Scholar
42. Fiore AE, Ujeki TM, Broder K, Finelli L, Euler GL, Singleton JA et al. Prevention and control of influenza with vaccines: recommendation of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59(RR-8): 1-62. PubMed | Google Scholar
43. Anselem O, Floret D, Tsatsaris V, Goffinet F, Launay O. Grippe au cours de la grossesse. Presse Med. 2013;42(11): 1453-1460. PubMed | Google Scholar
44. Schanzer DL, Schwartz B. Impact of seasonal and pandemic influenza on emergency department visits, 2003-2010, Ontario, Canada. Acad Emerg Med. 2013 Apr;20(4): 388-97. PubMed | Google Scholar

45. Tempia S, Walaza S, Moyes J, Cohen AL, von Mollendorf C, Treurnicht FK et al. Risk factors for influenza-associated severe acute respiratory illness hospitalization in South Africa, 2012-2015. OFID. 2017;4(1): ofw262. PubMed | Google Scholar

46. Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with hospitalization for influenza associated severe acute respiratory illness in South Africa: a case-population study. Vaccine. 2016 November 04;34(46): 5649-5655. PubMed | Google Scholar

47. Ho A, Mallewa J, Peterson I, SanJoaquin M, Garg S, Bar-Zeev N et al. Epidemiology of severe acute respiratory illness and risk factors for influenza infection and clinical severity among adults in Malawi, 2011-2013. Am J Trop Med Hyg. 2018;99(3): 772-779. PubMed | Google Scholar

48. Durigon GS, Oliveira DBL, Felicio MCC, Finelli C, Pereira MFB, Storni JG et al. Poor outcome of acute respiratory infection in young children with underlying health condition in Brazil. Int J of Inf Disease. 2015;34: 3-7. PubMed | Google Scholar

49. Launes C, García-Garcia JJ, Martínez-Planas A, Moraga F, Soldevila N, Astigarraga I et al. Clinical features of influenza disease in admitted children during the first post pandemic season and risk factors for hospitalization: a multicentre Spanish experience. Clinical Microbiology and Infection, European Society of Clinical Microbiology and Infectious Diseases, CMI. 2012;19(3): E157-E162. PubMed | Google Scholar

**Table 1:** number of SARI cases recruited and their influenza positivity rates per clinical ward (2016/2017 and 2017/2018 season)

| Clinical service       | 2016-2017 season | 2017-2018 season |
|------------------------|------------------|------------------|
| Pediatrics             | 527              | 434              |
|                        | 0,4%             | 7,6%             |
| Pulmonology            | 89               | 142              |
|                        | 3,4%             | 7,6%             |
| Medicine               | 1                | 40               |
|                        | 0,0%             | 22,5%            |
| Intensive Care Unit    | 66               | 87               |
|                        | 9,1%             | 20,7%            |
| Emergencies            | 7                | 33               |
|                        | 0,0%             | 9,4%             |

(*) Source : NIC-INH
Table 2: number of SARI cases with co-morbidities sampled and their influenza positivity rate (2016/2017 and 2017/2018 season)

| Risk factor (or comorbidity) | 2016-2017 season | 2017-2018 season | Both seasons |
|------------------------------|-------------------|-------------------|--------------|
| Diabetes                     |                   |                   |              |
| Number                       | 19                | 56                | 75           |
| Risk factor proportion       | 2,7%              | 6,8%              | 4,9%         |
| Risk factor positivity rate  | 5,3%              | 32,6%             | 24,6%        |
| Obesity                      |                   |                   |              |
| Number                       | 10                | 9                 | 19           |
| Risk factor proportion       | 1,4%              | 1,1%              | 1,2%         |
| Risk factor positivity rate  | 10,0%             | 37,5%             | 22,2%        |
| Asthma                       |                   |                   |              |
| Number                       | 39                | 68                | 107          |
| Risk factor proportion       | 5,5%              | 8,3%              | 7,0%         |
| Risk factor positivity rate  | 15,4%             | 11,9%             | 13,2%        |
| Chronic Respiratory Disease  |                   |                   |              |
| Number                       | 40                | 75                | 115          |
| Risk factor proportion       | 5,7%              | 9,2%              | 7,6%         |
| Risk factor positivity rate  | 7,5%              | 18,3%             | 14,4%        |
| Chronic Heart Disease        |                   |                   |              |
| Number                       | 24                | 35                | 59           |
| Risk factor proportion       | 3,4%              | 4,3%              | 3,9%         |
| Risk factor positivity rate  | 0,0%              | 32,3%             | 18,2%        |
| Chronic Renal Failure        |                   |                   |              |
| Number                       | 6                 | 23                | 29           |
| Risk factor proportion       | 0,9%              | 2,8%              | 1,9%         |
| Risk factor positivity rate  | 0,0%              | 27,3%             | 21,4%        |
| Chronic Neurological Disease |                   |                   |              |
| Number                       | 2                 | 4                 | 6            |
| Risk factor proportion       | 0,3%              | 0,5%              | 0,4%         |
| Risk factor positivity rate  | 0,0%              | 25,0%             | 16,7%        |
| Chronic Hematological Disease|                   |                   |              |
| Number                       | 13                | 13                | 26           |
| Risk factor proportion       | 1,8%              | 1,6%              | 1,7%         |
| Risk factor positivity rate  | 7,7%              | 25,0%             | 16,0%        |
| Pregnancy (**)               |                   |                   |              |
| Number                       | 9                 | 5                 | 14           |
| Risk factor proportion       | 3,10%             | 1,80%             | 2,40%        |
| Risk factor positivity rate  | 11,1%             | 40,0%             | 21,4%        |

(*) Source : NIC-INH (**) Only females
Table 3: bi-variate analysis for evaluating the risk factors of influenza-associated SARI with a sample of 381 influenza-positive cases (2016/2017 and 2017/2018 season)

| Variable                              | SARI Positive n (%) | ILI Positive n (%) | OR Crude | CI95%     | P Value |
|---------------------------------------|---------------------|--------------------|----------|-----------|---------|
| **Socio-demographic characteristics** |                     |                    |          |           |         |
| Male sex                              | Yes 79 (61.2%)      | Yes 105 (41.7%)    | 2.2      | [1.4-3.4] | <0.001  |
|                                       | No 50 (38.8%)       | Yes 147 (58.3%)    |          |           |         |
| Age > 65 years                         | Yes 30 (23.3%)      | Yes 7 (2.8%)       | 10.6     | [4.5-24.9]| <10-11  |
|                                       | No 99 (76.7%)       | Yes 245 (97.2%)    |          |           |         |
| **Context**                           |                     |                    |          |           |         |
| Influenza vaccination during the current season | Yes 2 (1.6%)      | Yes 7 (2.8%)       | 0.6      | [0.1-2.7] | 0.36(*) |
|                                       | No 127 (98.4%)      | Yes 245 (97.2%)    |          |           |         |
| Existence of cases in the surroundings | Yes 9 (7.0%)       | Yes 95 (37.3%)     | 0.1      | [0.06-0.3]| <10-11  |
|                                       | No 120 (93.0%)      | Yes 157 (62.3%)    |          |           |         |
| **Co-morbidities**                    |                     |                    |          |           |         |
| Diabetes                              | Yes 16 (12.4%)      | Yes 4 (1.6%)       | 8.8      | [2.9-26.9]| <10-5   |
|                                       | No 113 (87.6%)      | Yes 248 (98.4%)    |          |           |         |
| Asthma                                | Yes 14 (10.9%)      | Yes 3 (1.2%)       | 10.1     | [2.8-35.9]| <10-4   |
|                                       | No 115 (89.1%)      | Yes 249 (98.8%)    |          |           |         |
| Chronic Respiratory Disease           | Yes 16 (12.4%)      | Yes 2 (0.8%)       | 17.7     | [4.0-78.3]| <10-5   |
|                                       | No 113 (87.6%)      | Yes 250 (99.2%)    |          |           |         |
| Chronic Heart Disease                 | Yes 10 (7.8%)       | Yes 5 (2.0%)       | 4.2      | [1.4-12.4]| 0.006   |
|                                       | No 119 (92.2%)      | Yes 247 (98.0%)    |          |           |         |
| Chronic Renal Failure                 | Yes 6 (4.7%)        | Yes 1 (0.4%)       | 12.2     | [1.5-102.8]| 0.007(*)|
|                                       | No 123 (95.3%)      | Yes 251 (99.6%)    |          |           |         |
| Chronic Neurological Disease          | Yes 1 (0.8%)        | Yes 0 (0.0%)       | Ind.     | Ind.      | 0.33(*) |
|                                       | No 128 (99.2%)      | Yes 252 (100.0%)   |          |           |         |
| Chronic Hematological Disease         | Yes 4 (3.1%)        | Yes 0 (0.0%)       | Ind.     | Ind.      | 0.01(*) |
|                                       | No 125 (96.9%)      | Yes 252 (100.0%)   |          |           |         |
| Pregnancy                             | Yes 3 (5.9%)        | Yes 2 (1.4%)       | 4.5      | [0.7-27.9]| 0.11(*) |
|                                       | No 48 (94.1%)       | Yes 145 (98.6%)    |          |           |         |
| Obesity                               | Yes 4 (3.1%)        | Yes 2 (0.8%)       | 4.0      | [0.7-22.1]| 0.10 (*)|
|                                       | No 125 (96.9%)      | Yes 250 (99.2%)    |          |           |         |

(*) Use of the exact Fisher test because of the too small number in cells. (**) Only females
Table 4: multivariate logistic regression model for evaluating the risk factors of influenza-associated SARI with a sample of 381 influenza-positive cases (2016/2017 and 2017/2018 season)

| Variable                                      | OR adjusted | CI 95%   | P-Value |
|-----------------------------------------------|-------------|----------|---------|
| Male sex (Yes/No)                             | 2.1         | 1.3      | 3.5     | 0.005   |
| Age >=65 years (Yes/No)                       | 5.4         | 1.9      | 15.6    | 0.002   |
| Existence of cases in the surroundings (Yes/No)| 0.1         | 0.05     | 0.3     | <0.001  |
| Diabetes (Yes/No)                             | 7.5         | 1.7      | 32.8    | 0.007   |
| Asthma (Yes/No)                               | 2.9         | 0.7      | 12.2    | 0.15    |
| Chronic Respiratory Disease (Yes/No)          | 10.9        | 2.0      | 58.4    | 0.005   |
| Chronic Heart Disease (Yes/No)                | 2.3         | 0.5      | 10.5    | 0.29    |
| Chronic Renal Failure (Yes/No)                | 8.2         | 0.8      | 79.7    | 0.07    |

Figure 1: influenza positivity rate by clinical syndrome (2016/2017 and 2017/2018 season)
Figure 2: SARI cases per age range (2016/2017 and 2017/2018 season)

Figure 3: positive rate per age range of SARI cases, all-season combined (2016/2017 and 2017/2018 season)
Figure 4: positive rate per age range of ILI cases, all seasons combined (2016/2017 and 2017/2018 season)